We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Epistem | LSE:EHP | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 85.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
TIDMGDR
Genedrive PLC
18 April 2018
For release RNS Reach: 18 April 2018
genedrive plc ("genedrive" or the "Company")
genedrive plc to Present at the UK Investor Show
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, today announces that David Budd, CEO and Matthew Fowler, CFO, will be attending the UK Investor Show, Britain's largest one day investor event.
The event will take place on Saturday 21(st) April 2018 at the Queen Elizabeth II Conference Centre in Westminster, London. The Company will be based at stand 72 from 8.30am until 5.30pm to discuss genedrive's recent progress and growth strategy with existing and prospective investors.
For more details on the event please visit: www.ukinvestorshow.com
- Ends -
For further details please contact:
genedrive plc
David Budd: CEO +44 (0)161 989 0245
Matthew Fowler: CFO
Peel Hunt LLP
James Steel +44 (0)207 418 8900
Oliver Jackson
Stanford Capital Partners Limited +44 (0) 0203 815 8880
Patrick Claridge
Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Matthew Neal
Laura Thornton
genedrive@consilium-comms.com
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive(R) HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive(R) platform in the EMEA and SE Asia (ex India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive(R) HCV ID Kit and Genedrive(R) platform in India.
Further details can be found at: www.genedriveplc.com and www.genedrive.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUBAARWAASAUR
(END) Dow Jones Newswires
April 18, 2018 02:01 ET (06:01 GMT)
1 Year Epistem Chart |
1 Month Epistem Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
